Phase I trial of novel CAR-T cell therapy for pediatric midline gliomas
Physician's Weekly,
1. Approximately 88% of patients with GD2-positive diffuse midline glioma or other progressive CNS tumours receiving C7R-GD2.CART…
FROM THE LABS: CAR T cell therapy for pediatric brain cancer warrants further study
Baylor College of Medicine,
This study shows that this therapy can effectively get to the tumor, and the addition of C7R safely augments antitumor activity.
CAR T cell therapy for pediatric brain cancer warrants further study
Health Medicine Network,
ummary of patient outcomes. (A) Swimmer plot, (B) MRI case examples (patient 5/10), and (C) MRI case examples (patient 8).